Decreased Paraoxonase-1 Activity is Associated with Alterations of High-density Lipoprotein Particles in Chronic Liver Impairment

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2010 May 18

PMID 20470383

Citations 17

Authors

Judit Marsillach

Gerard Aragones

Bharti Mackness

Michael Mackness

Anna Rull

Raul Beltran-Debon

Juan Pedro-Botet

Carlos Alonso-Villaverde

Jorge Joven

Jordi Camps

Affiliations

Soon will be listed here.

Abstract

Background: Paraoxonase-1 (PON1), a lactonase synthesized by the liver, circulates in blood bound to high-density lipoproteins (HDL). This enzyme is thought to degrade oxidized phospholipids and play an important role in the organism's antioxidant and anti-inflammatory system. Chronic liver diseases are characterized by decreased serum PON1 activity. The aim of the present study was to investigate the compositional changes in HDL that could influence PON1 activity in liver impairment.

Methods: The study was performed in samples from five patients with advanced liver cirrhosis and with preserved renal function, chosen on the basis of having low serum PON1 activity and high serum PON1 concentration. As a control group, we accessed five healthy volunteers from among our hospital staff. Lipid and protein compositional analysis of lipoprotein particles were done by high-performance liquid chromatography, gel electrophoresis, and Western-Blot.

Results: HDL particles from cirrhotic patients had an increased phospholipid content that was inversely correlated to PON1 activity. The HDL particles contained high levels of PON1 that corresponded, in part, to an immunoreactive protein of high molecular weight (55 kDa) not present in control subjects. This protein was identified as glycosylated PON1 and was also present in biopsies from patients with steatosis and from rats with CCl(4)-induced hepatic impairment. These changes were associated with an increased plasma concentration of markers of oxidative stress, inflammation and fibrogenesis.

Conclusion: Abnormalities in the composition of lipids and proteins of HDL particles, including PON1 glycosylation, are associated with the decrease in serum PON1 activity in patients with liver disease. These alterations may adversely affect the protective role of HDL against oxidative stress and inflammation in these patients.

Citing Articles

Molecular Structure of Paraoxonase-1 and Its Modifications in Relation to Enzyme Activity and Biological Functions-A Comprehensive Review.

Lewon-Mrozek D, Kurzynoga J, Jedrzejewski P, Kedzierska K, Partyka A, Kuriata-Kordek M Int J Mol Sci. 2024; 25(23).

PMID: 39684839 PMC: 11642642. DOI: 10.3390/ijms252313129.

Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity.

Dong L, Dong C, Yu Y, Jiao X, Zhang X, Zhang X Clin Transl Oncol. 2024; 27(2):612-629.

PMID: 39031295 DOI: 10.1007/s12094-024-03598-y.

Heterocyclic Amines Disrupt Lipid Homeostasis in Cryopreserved Human Hepatocytes.

Walls K, Joh J, Hong K, Hein D Cardiovasc Toxicol. 2024; 24(8):747-756.

PMID: 38851663 PMC: 11300155. DOI: 10.1007/s12012-024-09874-1.

Serum Arylesterase, Paraoxonase, and Lactonase Activities and Paraoxonase-1 Concentrations in Morbidly Obese Patients and Their Relationship with Non-Alcoholic Steatohepatitis.

Castane H, Jimenez-Franco A, Martinez-Navidad C, Placed-Gallego C, Cambra-Cortes V, Perta A Antioxidants (Basel). 2023; 12(12).

PMID: 38136158 PMC: 10741051. DOI: 10.3390/antiox12122038.

mTOR-dependent loss of PON1 secretion and antiphospholipid autoantibody production underlie autoimmunity-mediated cirrhosis in transaldolase deficiency.

Winans T, Oaks Z, Choudhary G, Patel A, Huang N, Faludi T J Autoimmun. 2023; 140:103112.

PMID: 37742509 PMC: 10957505. DOI: 10.1016/j.jaut.2023.103112.

References

Furlong C, Suzuki S, Stevens R, Marsillach J, Richter R, Jarvik G . Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact. 2010; 187(1-3):355-61. PMC: 3035622. DOI: 10.1016/j.cbi.2010.03.033. View

Sorenson R, Bisgaier C, Aviram M, Hsu C, Billecke S, La Du B . Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999; 19(9):2214-25. DOI: 10.1161/01.atv.19.9.2214. View

Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza J . Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol. 2007; 27(8):1843-9. DOI: 10.1161/ATVBAHA.107.145672. View

Navab M, Berliner J, Subbanagounder G, Hama S, Lusis A, Castellani L . HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001; 21(4):481-8. DOI: 10.1161/01.atv.21.4.481. View

Gasso M, Rubio M, Varela G, Cabre M, Caballeria J, Alonso E . Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol. 1996; 25(2):200-5. DOI: 10.1016/s0168-8278(96)80074-2. View

Rozenberg O, Rosenblat M, Coleman R, Shih D, Aviram M . Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med. 2003; 34(6):774-84. DOI: 10.1016/s0891-5849(02)01429-6. View

Cockerill G, Rye K, Gamble J, Vadas M, Barter P . High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995; 15(11):1987-94. DOI: 10.1161/01.atv.15.11.1987. View

Ribas V, Sanchez-Quesada J, Anton R, Camacho M, Julve J, Escola-Gil J . Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res. 2004; 95(8):789-97. DOI: 10.1161/01.RES.0000146031.94850.5f. View

Mackness M, Arrol S, Abbott C, Durrington P . Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993; 104(1-2):129-35. DOI: 10.1016/0021-9150(93)90183-u. View

10.

Huuskonen J, Olkkonen V, Jauhiainen M, Ehnholm C . The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis. 2001; 155(2):269-81. DOI: 10.1016/s0021-9150(01)00447-6. View

11.

Zamara E, Novo E, Marra F, Gentilini A, Romanelli R, Caligiuri A . 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol. 2003; 40(1):60-8. DOI: 10.1016/s0168-8278(03)00480-x. View

12.

James R, Deakin S . The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004; 37(12):1986-94. DOI: 10.1016/j.freeradbiomed.2004.08.012. View

13.

Ferre N, Camps J, Prats E, Vilella E, Paul A, Figuera L . Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem. 2002; 48(2):261-8. View

14.

Watson A, Berliner J, Hama S, La Du B, Faull K, Fogelman A . Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995; 96(6):2882-91. PMC: 185999. DOI: 10.1172/JCI118359. View

15.

Blanco-Vaca F, Escola-Gil J, Martin-Campos J, Julve J . Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001; 42(11):1727-39. View

16.

Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C . Isoprostanes and hepatic fibrosis. Mol Aspects Med. 2007; 29(1-2):43-9. DOI: 10.1016/j.mam.2007.09.011. View

17.

Lagrost L, Athias A, Gambert P, LALLEMANT C . Comparative study of phospholipid transfer activities mediated by cholesteryl ester transfer protein and phospholipid transfer protein. J Lipid Res. 1994; 35(5):825-35. View

18.

Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M . Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004; 318(3):680-3. DOI: 10.1016/j.bbrc.2004.04.056. View

19.

Marsillach J, Mackness B, Mackness M, Riu F, Beltran R, Joven J . Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med. 2008; 45(2):146-57. DOI: 10.1016/j.freeradbiomed.2008.03.023. View

20.

Marsillach J, Bertran N, Camps J, Ferre N, Riu F, Tous M . The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clin Biochem. 2005; 38(12):1138-40. DOI: 10.1016/j.clinbiochem.2005.09.006. View